Definium's oral LSD candidate passes first Phase 3 trial in generalized anxiety disorder

Definium Therapeutics announced that its oral LSD candidate has successfully completed a Phase 3 trial in generalized anxiety disorder.

The study met its primary endpoints, marking the first of two planned Phase 3 trials for the drug. This follows a positive result earlier this year in a trial for a severe form of anxiety.

The company said the outcome positions the candidate for further development and potential regulatory submission, underscoring its focus on psychedelic therapies for mental health.